Developing a systematic approach to safer medication use during pregnancy: summary of a Centers for Disease Control and Prevention–convened meeting - 25/07/14
, Meghan T. Frey, MA, MPH a, b, Sonia Hernandez-Diaz, MD, DrPH c, Michael F. Greene, MD d, Christina D. Chambers, PhD, MPH e, Leyla Sahin, MD, FACOG f, Beth A. Collins Sharp, PhD, RN, FAAN g, Margaret A. Honein, PhD, MPH aCet article a été publié dans un numéro de la revue, cliquez ici pour y accéder
Abstract |
To address information gaps that limit informed clinical decisions on medication use in pregnancy, the Centers for Disease Control and Prevention (CDC) solicited expert input on a draft prototype outlining a systematic approach to evaluating the quality and strength of existing evidence for associated risks. The draft prototype outlined a process for the systematic review of available evidence and deliberations by a panel of experts to inform clinical decision making for managing health conditions in pregnancy. At an expert meeting convened by the CDC in January 2013, participants divided into working groups discussed decision points within the prototype. This report summarizes their discussions of best practices for formulating an expert review process, developing evidence summaries and treatment guidance, and disseminating information. There is clear recognition of current knowledge gaps and a strong collaboration of federal partners, academic experts, and professional organizations willing to work together toward safer medication use during pregnancy.
Le texte complet de cet article est disponible en PDF.Key words : Centers for Disease Control and Prevention, expert review, medications, pregnancy, teratogens
Plan
| This work was supported in part by an appointment to the Research Participation Program at the Centers for Disease Control and Prevention (CDC) administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the US Department of Energy and the CDC (M.T.F.). |
|
| Dr Hernandez-Diaz has been an adviser for pregnancy registries sponsored by Novartis and GSK Biologicals and has received training grants from Pfizer, Millennium, and PhRMA. Dr Chambers received research funding support from Amgen, Ab-Vie, Bristol-Myers Squibb, GlaxoSmithKline, Novartis, Sanofi-Genzyme, Roche-Genentech, Pfizer, Janssen, Teva, Sandoz, Kali, and Apotex. The remaining authors report no conflict of interest. |
|
| The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or other agencies. |
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?